• Progressed two major phase 2 clinical trial programs in Alzheimer's disease and depression
• Received $9.0 million R&D tax incentive rebate
• Funded to mid-late CY 2026

Actinogen Medical Ltd reported its half-year financial results for the period ended 31 December 2024. The company's principal activity during the period focused on the ongoing clinical development of Xanamem (emestedastat), a unique inhibitor of the 11β-HSD1 enzyme that achieves target engagement in the brain. Key highlights include: progressing two major phase 2 clinical trial programs in Alzheimer's disease (XanaMIA) and major depressive disorder (XanaCIDD); receiving a $9.0 million R&D tax incentive rebate in November 2024; and securing funding to mid-late CY 2026. The company also announced the appointment of its inaugural Chief Commercial Officer, regulatory meetings, and ongoing partnering discussions. Actinogen continues to prepare for the commercialization of Xanamem, leveraging its robust intellectual property protection. The company presented at several international conferences and conducted meetings at industry gatherings to evaluate potential value-add regional and global business development opportunities.

Actinogen is focused on the late-stage clinical development of its lead drug candidate Xanamem, including the implementation of the XanaMIA phase 2b/3 Alzheimer's disease trial and meetings with regulators for both Alzheimer's disease and major depressive disorder to understand registrational requirements for marketing approvals. The company continues to engage in partnering discussions and investigate grant opportunities to support the expansion of its clinical trial programs.